MinervaX Strengthens Executive Leadership Team with Two Strategic Appointments as it Advances its Maternal GBS Vaccine Towards Pivotal Trial Initiation
- The appointments of Jamila Louahed as CDO and Hans Henrik Chrois Christensen as CFO bring late‑stage development, global regulatory and operational expertise as MinervaX enters its next phase of growth
- Builds on robust Phase II results, paving the way for a registrational trial and advancing efforts to meet the urgent global need for a GBS vaccine
Copenhagen, Denmark, April 15, 2026 – MinervaX ApS, a privately held Danish biotechnology company developing a novel, prophylactic vaccine against Group B Streptococcus (GBS), today announces the appointments of Jamila Louahed as Chief Development Officer and Hans Henrik Chrois Christensen as Chief Financial Officer. These appointments strengthen MinervaX’s capabilities as the company advances its novel GBS vaccine toward pivotal trial initiation in the maternal indication and continues to scale its operations.
